Freestone Grove Partners LP Makes New Investment in Oruka Therapeutics, Inc. $ORKA

Freestone Grove Partners LP bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 22,421 shares of the company’s stock, valued at approximately $2,134,000.

Several other institutional investors also recently modified their holdings of the business. Algert Global LLC lifted its holdings in Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after acquiring an additional 180 shares during the period. Royal Bank of Canada boosted its position in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Kennedy Capital Management LLC boosted its position in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after purchasing an additional 626 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the period. 56.44% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ORKA has been the topic of a number of recent analyst reports. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. BTIG Research reissued a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, UBS Group lifted their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $91.14 on Friday. The business has a fifty day simple moving average of $94.60 and a two-hundred day simple moving average of $67.51. Oruka Therapeutics, Inc. has a 1 year low of $14.61 and a 1 year high of $115.51. The company has a market capitalization of $6.03 billion, a P/E ratio of -44.90 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, Director Carl Dambkowski sold 12,583 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the sale, the director directly owned 38,743 shares of the company’s stock, valued at $2,716,271.73. This represents a 24.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at $64,503,670.20. This represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 83,116 shares of company stock worth $6,636,533. Insiders own 23.49% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.